Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.

PubWeight™: 1.52‹?› | Rank: Top 4%

🔗 View Article (PMID 12372721)

Published in Lancet Oncol on October 01, 2002


Jonathan D Schwartz1, Myron Schwartz, John Mandeli, Max Sung

Author Affiliations

1: Mount Sinai School of Medicine, Medical Oncology, New York, NY 10029, USA.

Articles citing this

A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 2.50

Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87

Current management strategy of hepatocellular carcinoma. World J Gastroenterol (2009) 1.79

Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg (2007) 1.70

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol (2006) 1.60

The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One (2015) 1.46

Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer (2012) 1.24

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol (2016) 1.16

Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection. World J Surg (2008) 1.06

Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06

Surgical treatment of hepatocellular carcinoma. HPB (Oxford) (2005) 1.04

HCC: current surgical treatment concepts. Langenbecks Arch Surg (2012) 1.03

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01

Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol (2003) 0.99

Management of hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.96

A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer (2015) 0.85

Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol (2012) 0.85

Acute heart failure caused by a giant hepatocellular metastatic tumor of the right atrium. J Cardiothorac Surg (2011) 0.84

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination. PPAR Res (2012) 0.83

A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol (2013) 0.83

Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging (2005) 0.82

Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg (2013) 0.82

Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells. Cancer Biol Ther (2014) 0.82

Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol (2010) 0.82

Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One (2013) 0.81

Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther (2015) 0.81

Recent advances in liver resection for hepatocellular carcinoma. Front Surg (2014) 0.81

Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat. Dig Dis Sci (2004) 0.80

Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2015) 0.79

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 0.79

Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol (2014) 0.79

Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis (2009) 0.79

Hepatocellular carcinoma: a systems biology perspective. Front Physiol (2013) 0.79

Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci (2013) 0.79

Current status of multimodal & combination therapy for hepatocellular carcinoma. Indian J Med Res (2012) 0.78

The Histologic Cut-off Point for Adjacent and Remote Non-neoplastic Liver Parenchyma of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. Korean J Pathol (2012) 0.78

RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget (2015) 0.77

Future perspectives for hepatocellular carcinoma. HPB (Oxford) (2003) 0.76

Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med (2015) 0.76

A brief comment on liver resection for hepatocellular carcinoma. Gastroenterol Rep (Oxf) (2013) 0.75

Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma. Int J Clin Exp Med (2015) 0.75

Enhancement of leukocyte adhesion after percutaneous irradiation in rats with hepatocellular carcinoma. World J Gastroenterol (2005) 0.75

Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol (2015) 0.75

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. J Med Case Rep (2011) 0.75

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett (2016) 0.75

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis (2017) 0.75

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75

Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget (2017) 0.75

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84

Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax (2010) 1.80

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65

Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res (2003) 1.20

rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13

Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09

Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09

Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol (2006) 1.03

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02

Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol (2010) 1.00

Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95

Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells. Oncol Rep (2007) 0.94

Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93

Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91

Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91

Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst (2006) 0.90

Assessment of inspiratory flow limitation in children with sleep-disordered breathing by a nasal cannula pressure transducer system. Pediatr Pulmonol (2002) 0.90

The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant (2004) 0.88

Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87

Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87

Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87

Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86

Downstaging cancer in rural Africa. Int J Cancer (2014) 0.85

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol (2004) 0.85

Establishing an international training program for surgical residents. J Surg Educ (2007) 0.85

Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84

Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes (2005) 0.84

Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83

KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. Am J Pathol (2012) 0.83

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol (2010) 0.83

Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci (2009) 0.83

Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol (2014) 0.82

Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas (2011) 0.82

Adult-adult living donor liver transplantation. J Gastrointest Surg (2004) 0.82

Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2011) 0.82

Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett (2003) 0.82

Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis (2006) 0.81

The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer (2014) 0.81

Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl (2008) 0.81

Liver transplantation for hepatocellular carcinoma. Hepatol Res (2007) 0.81

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol (2005) 0.80

Hand-assisted laparoscopic donor hepatectomy for living related transplantation in the porcine model. Surg Laparosc Endosc Percutan Tech (2002) 0.80

Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice. Genes Cancer (2011) 0.79

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. J Surg Oncol (2014) 0.79

A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. Am J Clin Oncol (2011) 0.78

Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. J Immunother (2016) 0.78

Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB (Oxford) (2012) 0.77

Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis (2008) 0.77

Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Am J Hematol (2010) 0.77

Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol (2013) 0.77

Clinical pathways for pancreatic neuroendocrine tumors. J Gastrointest Cancer (2012) 0.76

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res (2013) 0.76

A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells. Proc Natl Acad Sci U S A (2004) 0.76

Unresectable squamous cell carcinoma of donor origin treated with immunosuppression withdrawal and liver retransplantation. Am J Transplant (2004) 0.76

Surgical treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) (2010) 0.75

Reply:. Hepatology (2013) 0.75

Retraction: A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2010) 0.75

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 0.75

Outcomes in hepatitis B transplant candidates with or without hepatocellular carcinoma: UNOS policy vindicated! Liver Transpl (2007) 0.75

Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas (2016) 0.75

Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease. Ann Surg Oncol (2012) 0.75

Decision-Making in Breast Cancer Surgery: Where Do Patients Go for Information? Am Surg (2016) 0.75

HazDat in action. Occup Health Saf (2006) 0.75